SCHEMBL16246796

SCHEMBL16246796

NC(=O)c1n[nH]c2ccc(Cl)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 4/20 0.48
JAK1 P23458 3/20 0.48
ROCK1 Q13464 1/20 0.47
MAP2 P11137 3/20 0.47
RBP4 P02753 1/20 0.44
AURKA O14965 1/20 0.44
AURKB Q96GD4 1/20 0.44
DYRK1A Q13627 2/20 0.44
NTRK1 P04629 1/20 0.44
WNT1 P04628 1/20 0.44
CLK2 P49760 1/20 0.44
CLK3 P49761 1/20 0.44
FADS1 O60427 1/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
F7 P08709 1/20 0.42
F3 P13726 1/20 0.42
MAP2K4 P45985 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15540985 0.87 MAP2K4 (0.52) JAK2JAK1MAP2RBP4KDM4E
SCHEMBL27814101 0.86 ROCK1 (0.49) JAK2JAK1ROCK1RBP4DYRK1A
SCHEMBL570293 0.85 PRKAG1 (0.55) ROCK1F7F3MAP2K4
SCHEMBL17324736 0.83 ROCK1 (0.47) JAK2JAK1ROCK1MAP2RBP4
SCHEMBL23368472 0.83 GSK3B (0.47) JAK2JAK1DYRK1ANTRK1WNT1
SCHEMBL22518544 0.83 ROCK1 (0.53) JAK2JAK1ROCK1AURKAAURKB
SCHEMBL8877161 0.81 JAK2 (0.54) JAK2JAK1DYRK1ANTRK1WNT1
SCHEMBL15942818 0.80 MAP2K4 (0.62) JAK2JAK1DYRK1ANTRK1WNT1
SCHEMBL17039120 0.80 JAK2 (0.64) JAK2JAK1AURKAAURKBDYRK1A
SCHEMBL6195016 0.80 DYRK1A (0.44) JAK2JAK1DYRK1ANTRK1WNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3305778-A1 INHIBITORS OF PLASMA KALLIKREIN Kalvista Pharmaceuticals Limited (GB) 2018-04-11 EP claimed
EP-3027605-B1 NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2017-11-08 EP claimed
US-9737510-B2 Indazole compounds and a process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-08-22 US claimed
CN-106103427-A New indazole compound and preparation method thereof 科学与工业研究会 2016-11-09 CN claimed
US-20160185759-A1 NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-06-30 US claimed
EP-3027605-A1 NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF Council of Scientific & Industrial Research (IN) 2016-06-08 EP claimed
EP-2999697-A1 HETEROCYCLIC DERIVATES Kalvista Pharmaceuticals Limited (GB) 2016-03-30 EP claimed
WO-2015015519-A1 NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-02-05 WO claimed
WO-2014188211-A1 HETEROCYCLIC DERIVATES KALVISTA PHARMACEUTICALS LIMITED (GB) 2014-11-27 WO claimed
EP-3305778-B1 INHIBITORS OF PLASMA KALLIKREIN KALVISTA PHARMACEUTICALS LTD (GB) 2022-01-19 EP disclosed
EP-3305778-A1 INHIBITORS OF PLASMA KALLIKREIN Kalvista Pharmaceuticals Limited (GB) 2018-04-11 EP disclosed
EP-3027605-B1 NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2017-11-08 EP disclosed
EP-3027605-B1 NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2017-11-08 EP disclosed
US-9737510-B2 Indazole compounds and a process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-08-22 US disclosed
EP-3027605-A1 NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF Council of Scientific & Industrial Research (IN) 2016-06-08 EP disclosed
US-20160108036-A1 HETEROCYCLIC DERIVATES KALVISTA PHARMACEUTICALS LIMITED (GB) 2016-04-21 US disclosed
EP-2999697-A1 HETEROCYCLIC DERIVATES Kalvista Pharmaceuticals Limited (GB) 2016-03-30 EP disclosed
WO-2015015519-A1 NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-02-05 WO disclosed
WO-2015015519-A1 NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-02-05 WO disclosed
WO-2014188211-A1 HETEROCYCLIC DERIVATES KALVISTA PHARMACEUTICALS LIMITED (GB) 2014-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185759-A1 NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF GPR119, INSR, CYP11B1 JAK2 1061/4885JAK1 602/4885ROCK1 799/4885
US-20160108036-A1 HETEROCYCLIC DERIVATES BDKRB1, KLKB1, BDKRB2 JAK2 1553/4885JAK1 2035/4885ROCK1 839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.